**Multiple classes of bactericidal antibiotics cause DNA double strand breaks in
*Staphylococcus aureus***

Rebecca S. Clarke¹, Kam Pou Ha^{1,2} and Andrew M. Edwards^{1#}

¹ MRC Centre for Molecular Bacteriology and Infection, Imperial College London, Armstrong Rd, London, SW7 2AZ, UK.

² Present address: Université Paris-Saclay, CEA, CNRS, Institute for Integrative Biology of the Cell (I2BC), 91198, Gif-sur-Yvette, France.

[#] For correspondence:

a.edwards@imperial.ac.uk

Keywords: *Staphylococcus* / antibiotic / oxidative stress / DNA / DNA repair

Running title: Antibiotics cause *S. aureus* DNA damage

35 **Abstract**

36 Antibiotics inhibit essential bacterial processes, resulting in arrest of growth and in some cases cell
 37 death. Many antibiotics are also reported to trigger endogenous production of reactive oxygen
 38 species (ROS), which damage DNA and other macromolecules. However, the type of DNA damage
 39 that arises and the mechanisms used by bacteria to repair it are largely unclear. We found that
 40 several different classes of antibiotic triggered dose-dependent DNA damage in *Staphylococcus*
 41 *aureus*, including some bacteriostatic drugs. Damage was heterogenous and varied in magnitude
 42 between strains. However, antibiotic-triggered DNA damage led to double strand breaks, the
 43 processing of which by the RexAB helicase/nuclease complex triggered the SOS response and
 44 reduced staphylococcal susceptibility to most of the antibacterials tested. In most cases, DNA DSBs
 45 occurred under aerobic but not anaerobic conditions, suggesting a role for ROS. We conclude that
 46 DNA double strand breaks are a common occurrence during bacterial exposure to several different
 47 antibiotic classes and that repair of this damage by the RexAB complex promotes bacterial survival.

48

49

50

51

52 Introduction

53 *Staphylococcus aureus* is a common cause of both superficial and invasive infections [1]. Many of
 54 these infections, such as infective endocarditis and osteomyelitis can be difficult to treat, requiring
 55 lengthy courses of therapy [2,3,4,5,6,7,8,9,10]. Staphylococcal infections are also associated with a
 56 high rate of relapse and/or the development of chronic infections, even when the bacteria causing
 57 the infection appear to be fully antibiotic susceptible [2,3,4,5,6,7,8,9,10].
 58 There is, therefore, a pressing need to identify new approaches to enhance antibiotic efficacy. To do
 59 this, it is important to have a comprehensive understanding of the factors that influence bacterial
 60 susceptibility to antibiotics. For example, replication rate has been shown to correlate with
 61 susceptibility to several classes of antibiotic [11,12,13]. However, recent evidence suggests that
 62 metabolic activity is a better indicator of susceptibility than the replication rate, indicating that
 63 metabolism contributes to the bactericidal activity of certain antibacterial drugs [14]. This is because
 64 the inhibition of bacterial processes by bactericidal antibiotics leads to metabolic perturbations,
 65 which in turn result in the generation of reactive oxygen species (ROS) [15,16,17,18,19,20,21,22].
 66 These highly reactive molecules damage cellular molecules including DNA, lipids and protein and
 67 have been proposed to contribute to the lethality of bactericidal antibiotics [15,16,23,24,25,26].
 68 Antibiotic-triggered ROS production has been reported to occur in several different bacteria in
 69 response to many different classes of antibiotic [15,16,17,18,19,20,21,22]. However, the magnitude
 70 of the damage caused by antibiotic-triggered ROS production and the degree to which these radicals
 71 contribute to bacterial killing is unclear [27,28,29]. This issue is worth resolving because a greater
 72 understanding of the mechanisms by which bacteria repair the damage caused by ROS may help to
 73 identify new therapeutics that enhance antibiotic activity. For example, we have shown previously
 74 that the combination antibiotic co-trimoxazole (trimethoprim plus sulphamethoxazole) caused DNA
 75 double strand breaks (DSB) and induction of the SOS DNA repair response in an oxygen-dependent
 76 manner in the major human pathogen *Staphylococcus aureus* [30]. This DNA damage was lethal if
 77 not repaired, resulting in 50-5000-fold greater reduction in CFU counts of a mutant defective for DSB
 78 repair (*rexB::Tn*) relative to wild type *S. aureus*. As such, inhibitors of RexAB would be expected to
 79 significantly enhance the bactericidal activity of co-trimoxazole against *S. aureus*.
 80 To understand whether our findings with co-trimoxazole were applicable to other antibacterial
 81 drugs, we undertook a comprehensive analysis of multiple classes of antibiotics. This revealed that
 82 most antibiotics cause DNA damage in *S. aureus* under aerobic conditions, which results in DNA
 83 DSBs, since mutants lacking DNA DSB repair complex RexAB were more susceptible to antibiotic
 84 killing. Novel inhibitors that block staphylococcal DNA repair complex RexAB would, therefore, be
 85 expected to sensitise *S. aureus* to the bactericidal activity of multiple antibiotics.

86 **Results**

87 **Multiple classes of antibiotics cause DNA damage in *S. aureus***

88 DNA damage in most bacteria, including *S. aureus*, triggers activation of the SOS response, which
 89 leads to the transcription of genes whose products contribute to DNA repair [30,31,32,33,34]. These
 90 genes include *recA*, which encodes the RecA protein required for homologous recombination and,
 91 together with LexA, is a key regulator of the SOS response [31,32,33].

92 To determine whether antibiotics caused DNA damage in *S. aureus*, we used a *PrecA-gfp* reporter
 93 system in two distinct genetic backgrounds: SH1000, a methicillin-sensitive *S. aureus* (MSSA) strain,
 94 and JE2, a community-associated methicillin-resistant *S. aureus* (CA-MRSA) strain of the USA300
 95 lineage [30,34]. Co-trimoxazole was included as a control, since we have shown previously it triggers
 96 the SOS response in *S. aureus* [23].

97 These strains were then exposed to various classes of clinically relevant antibiotics across a range of
 98 concentrations that partially inhibited growth (Fig. S1). These included both bactericidal (co-
 99 trimoxazole, ciprofloxacin, nitrofurantoin, oxacillin, daptomycin, gentamicin) and bacteriostatic
 100 (chloramphenicol, linezolid) drugs.

101 As expected, we found that co-trimoxazole, ciprofloxacin, nitrofurantoin and oxacillin triggered SOS
 102 induction in both the SH1000 and JE2 strains (Fig. 1A,B,C,D,) [30,34,35,36]. DNA damage was also
 103 apparent during exposure to the bactericidal lipopeptide antibiotic daptomycin and the
 104 bacteriostatic drugs chloramphenicol and linezolid, albeit to varying degrees and with some
 105 differences between the two strains (Fig. 1E,F,G). However, we did not detect any induction of the
 106 SOS response during bacterial exposure to gentamicin at any of the concentrations used (Fig. 1H).
 107 Taken together, these data indicated that most clinically relevant classes of antibiotics, including
 108 bacteriostatic agents caused DNA damage in *S. aureus*.

109

Figure 1. Induction of the SOS response in *S. aureus* SH1000 and JE2 by diverse classes of antibiotics. (A-H) Induction of SOS measured by GFP expression driven from a *PrecA-gfp* reporter construct upon exposure to a range of concentrations of various antibiotics. Concentrations were chosen based on their ability to cause growth inhibition and represent multiples of the MIC of the individual strain as indicated in the key above each graph. GFP fluorescence was normalised to OD₆₀₀ to determine induction of SOS relative to cell density. Data represent the mean of 3 independent experiments (n = 3). Representative OD₆₀₀ measurements alone are shown in Fig. S1. Error bars represent standard deviation of the mean.

SOS induction is partly due to processing of DNA double strand breaks by the RexAB helicase/nuclease complex

We have shown previously that induction of the SOS response by co-trimoxazole is largely due to the processing of DNA double strand breaks (DSBs) by the AddAB-family RexAB nuclease/helicase complex [30,34,37]. Therefore, we determined whether SOS induction by other classes of antibiotics was also due to RexAB-mediated processing of DNA DSBs. As before, co-trimoxazole was included in these assays as a control.

To do this, we compared GFP fluorescence from wild type *S. aureus* JE2 and a *rexB::Tn* mutant defective for RexAB, both of which contained the *PrecA-gfp* reporter system, during exposure to the same panel of antibiotics as described for Figure 1 [30,34,38,39]. As expected from our previous work, we found that the lack of RexAB reduced *recA* induction relative to the wild type during exposure to co-trimoxazole (Fig. 2A) [30]. We also observed reduced *recA* expression in the *rexB::Tn* mutant relative to the wild type during exposure to the quinolone antibiotic ciprofloxacin, which is known to cause DNA DSBs (Fig. 2B) [40].

For nitrofurantoin, oxacillin, daptomycin, chloramphenicol and linezolid, we also observed lower levels of SOS induction in the *rexB::Tn* mutant relative to the wild type, although the differences between strains was not as profound as for co-trimoxazole and ciprofloxacin (Fig. 2C-H). As expected from previous data (Fig. 1G), no *recA* induction was observed from either wild type or *rexB::Tn* mutant during exposure to gentamicin (Fig. 2G). Therefore, as for co-trimoxazole, RexAB is required for maximal induction of SOS in response to DNA damage caused by several clinically relevant antibiotics, indicating that these drugs cause DNA DSBs in *S. aureus*.

Figure 2. *RexAB* is required for maximal induction of the SOS response during exposure to antibiotics. (A-H) Induction of SOS response of JE2 wild-type and *rexB* mutant measured by GFP expression upon exposure to a range of sub-lethal concentrations of antibiotics. Concentrations of antibiotic are labelled by multiple of the MIC of the wild-type strain. GFP fluorescence was normalised by OD₆₀₀ to determine induction of SOS relative to cell density (n = 3). Representative OD₆₀₀ measurements alone are shown in Fig. S1. Error bars represent standard deviation of the mean.

DNA DSB repair reduces bacterial susceptibility to several classes of antibiotics

The requirement of RexAB for maximal induction of the SOS response indicated that exposure to most antibiotics caused DNA DSBs [30,34]. Since DSBs are lethal if not repaired, we hypothesised that mutants defective for RexAB would be more susceptible than wild type strains to those antibiotics that triggered the SOS response.

To test this, we determined the minimum inhibitory concentration (MIC) of each antibiotic for wild type *S. aureus* SH1000 and JE2, and associated *rexB::Tn* mutants (Table 1). The *rexB* mutants in both JE2 and SH1000 strains were ≥ 2 -fold more susceptible to 7 of the 8 antibiotics tested conditions (Table 1). Importantly, the absence of RexAB increased the susceptibility of the MRSA strain JE2 to both oxacillin and ciprofloxacin 4-fold, despite this strain being resistant to both antibiotics.

The one exception was gentamicin, where the SH1000 *rexB::Tn* mutant was 2-fold more susceptible to the antibiotic, but the JE2 *rexB::Tn* mutant had the same MIC as the wild type strain, in keeping with the fact that this antibiotic did not trigger the SOS response under the conditions tested (Table 1). Taken together, the MIC data provide additional evidence that most antibiotics cause DNA DSBs in *S. aureus*.

Strain	SH1000 WT	SH1000 <i>rexB::Tn</i>	JE2 WT	JE2 <i>rexB::Tn</i>
Antibiotic				
Co-trimoxazole	0.25	0.125 (2-fold)	0.5	0.25 (2-fold)
Ciprofloxacin	0.125	0.0078 (16-fold)	16	4 (4-fold)
Nitrofurantoin	8	4 (2-fold)	16	4 (4-fold)
Oxacillin	0.125	0.06 (2-fold)	4	1 (4-fold)
Daptomycin	0.25	0.125 (2-fold)	0.25	0.125 (2-fold)
Chloramphenicol	4	1 (4-fold)	4	2 (2-fold)
Linezolid	1	0.25 (4-fold)	1	0.25 (4-fold)
Gentamicin	0.0625	0.031 (2-fold)	0.125	0.125 (no diff)

Table 1. MIC values ($\mu\text{g ml}^{-1}$) of *S. aureus* WT and *rexB* mutant in SH1000 and JE2 backgrounds for various antibiotics ($n \geq 3$; median MIC is shown). The fold reduction in MIC of the *rexB::Tn* mutants relative to the wild type are also shown.

DNA DSB repair promotes staphylococcal tolerance of several classes of antibiotics

We have shown previously that DNA DSB repair by RexAB enables staphylococcal tolerance of the combination antibiotic co-trimoxazole [30]. Since most of the other antibiotics we examined also caused DNA DSBs, leading to increased susceptibility of *rexB::Tn* mutants in MIC measurements, we hypothesised that RexAB would also contribute to bacterial survival during exposure to a supra-MIC concentration of these other anti-bacterial drugs.

To test this we exposed wild type *S. aureus* SH1000 and JE2, and associated *rexB::Tn* mutants to 10X the MIC of the wild type of each of the antibiotics used in previous assays and measured survival after 8 h incubation at 37 °C in an aerobic atmosphere (Fig. 3). Similar to the MIC assays, 6 of 8 antibiotics tested were more active against the *rexB::Tn* mutant relative to wild type bacteria, resulting in lower survival of the DNA repair defective strains (Fig. 3). The two antibiotics where there was no difference in survival between wild type and *rexB::Tn* mutants were linezolid and chloramphenicol, which are both bacteriostatic and did not reduce CFU counts of any of the strains (Fig. 3F,G). The remaining 6 antibiotics (co-trimoxazole, ciprofloxacin, oxacillin, nitrofurantoin, daptomycin, gentamicin), all of which are classified as bactericidal, caused significantly greater decreases in CFU counts of the *rexB::Tn* mutants relative to wild type bacteria (Fig. 3A,B,C,D,E,H). The increased susceptibility of the *rexB::Tn* mutants resulted in 5-500-fold greater reductions in CFU counts compared to wild type cells after 8h exposure to the 6 bactericidal antibiotics (Fig. 3A,B,C,D,E,H).

To test whether DNA DSBs caused by bactericidal antibiotics were due to endogenous ROS production, we repeated bactericidal activity assays under anaerobic conditions. As reported previously, co-trimoxazole lost bactericidal activity in the absence of oxygen, as did ciprofloxacin and gentamicin, the latter due to the reduction in membrane potential in the absence of oxygen [30,42] (Fig. 3A,B,H). The bactericidal antibiotics nitrofurantoin and daptomycin retained bactericidal activity under anaerobic conditions, but oxacillin did not (Fig. 3C,D,E). However, by contrast to aerobic conditions, nitrofurantoin and daptomycin were equally bactericidal against wild type and *rexB::Tn* mutants, suggesting that they caused DNA damage in a ROS dependent manner (Fig. 3).

The finding that loss of RexAB resulted in increased killing of both the SH1000 MSSA and JE2 MRSA strain by the frontline anti-staphylococcal penicillin oxacillin was particularly noteworthy because this indicated a mechanism by which MRSA strains could be re-sensitised to the antibiotic. Therefore, we repeated this assay and included mutants complemented with the *rexBA* operon [34] (Fig. 4). As expected, the *rexB::Tn* mutants were more susceptible to killing by oxacillin than wild type bacteria under aerobic but not anaerobic conditions. Complementation of mutations with

225 plasmids containing the *rexBA* operon, but not the plasmid alone, restored survival to wild type
 226 levels, confirming the role of RexAB in staphylococcal tolerance of oxacillin (Fig. 4).
 227 Taken together, these findings support previous work by showing that several diverse classes of
 228 antibiotics cause DNA damage under aerobic conditions, most likely via ROS generation [30]. The
 229 data presented here extend these previous observations by demonstrating that antibiotic-mediated
 230 DNA damage leads to DNA DSBs and that repair of these DSBs by the RexAB helicase/nuclease
 231 complex promotes bacterial survival during exposure to several different classes of antibiotic.
 232

233
 234
 235 **Figure 3. Lack of effective DNA repair increases the killing of *S. aureus* by bactericidal antibiotics**
 236 **under aerobic conditions. (A-H)** Survival of *S. aureus* WT and *rexB* mutant in SH1000 and JE2
 237 backgrounds after 8 h incubation at 37°C in TSB supplemented with 10x MIC. Survival was assessed

under aerobic (blue) or anaerobic (green) conditions (n = 3). Data were analysed by one-way ANOVA (* = P < 0.05) and presented as a box and whisker plot and presented as a box and whisker plot with error bars showing the full data range.

241

242

243

Figure 4. Complementation of the *rexB*::Tn mutant restores tolerance to oxacillin in *S. aureus* SH1000 and JE2. (A-D) Survival of *S. aureus* WT and *rex*B mutant in SH1000 and JE2 backgrounds after 8 h incubation at 37°C in TSB supplemented with 10x MIC. Survival was assessed under aerobic (blue) or anaerobic (green) conditions (n = 3). Data were analysed by one-way ANOVA (* = P < 0.05) and presented as a box and whisker plot with error bars showing the full data range.

249

250

251

252

253 Discussion

Staphylococcal infections are associated with high rates of treatment failure, even in the case of apparently drug-susceptible strains [1,2,3,4,5,6,7,8,9,10]. This, together with the threat posed by multi drug resistant MRSA strains, necessitates a greater understanding of how antibiotics function and the identification of opportunities to improve their efficacy [9].

257

258 There is compelling evidence that diverse antibiotics trigger metabolic perturbations in bacteria that
 259 lead to endogenous ROS production under aerobic conditions [14,15,16,17,18,19,20,21,22,23].
 260 However, the consequences of this for bacterial viability remain a matter of debate [27,28,29]. This
 261 is important because if endogenous ROS production is a common property of antibiotics then it
 262 could be exploited to enhance treatment outcomes, for example by designing inhibitors of bacterial
 263 processes that detoxify ROS or repair the damage it causes [30,34,43].
 264 To understand whether antibiotics cause ROS-mediated damage in *S. aureus*, we focussed on the
 265 degree to which antibiotic exposure resulted in bacterial DNA damage, since nucleic acids are
 266 frequently attacked by endogenous ROS, and the consequences of that damage for bacterial survival
 267 [24,25,26,30,34].
 268 Using a *PrecA-gfp* reporter assay we observed that the SOS response in *S. aureus* was triggered by
 269 several different classes of antibiotics, indicative of DNA damage. Whilst this was expected for DNA-
 270 targeting antibiotics such as the fluoroquinolone ciprofloxacin [40], SOS induction also occurred with
 271 antibiotics that do not directly target bacterial DNA such as oxacillin, daptomycin and linezolid. It has
 272 been shown that certain β -lactam antibiotics induce the SOS response in *E. coli* via the DpiBA two-
 273 component system rather than via DNA damage [44]. Although this mechanism has been
 274 hypothesised for *S. aureus*, our data show that *S. aureus rexBA* mutants were more susceptible to
 275 killing by oxacillin, demonstrating that DNA damage does occur during exposure to this β -lactam
 276 antibiotic and that this is at least partially responsible for triggering the SOS response. Our
 277 findings are in keeping with work showing that β -lactam antibiotics trigger endogenous ROS
 278 production via elevated TCA cycle activity in response to cell wall damage, leading to increased
 279 mutation rate [45].
 280 Whilst still a controversial topic, there is increasing evidence that many classes of antibiotics trigger
 281 the endogenous production of ROS. However, the degree to which these ROS contribute to
 282 bactericidal activity is less clear. Our data provide evidence that many antibiotics cause DNA
 283 damage, presumably via ROS since *rexB::Tn* mutants were as susceptible to most antibiotics under
 284 anaerobic conditions. However, this DNA damage appears to be largely tolerated by wild type
 285 bacteria via RexAB-mediated processing of DSBs, which triggers the SOS response to facilitate repair
 286 via homologous recombination.
 287 The production of ROS by bactericidal but not bacteriostatic antibiotics has been proposed to explain
 288 their differences in lethality. However, we observed SOS induction during exposure of *S. aureus* to
 289 the bacteriostatic antibiotics linezolid and chloramphenicol, but not the bactericidal antibiotic
 290 gentamicin. Surprisingly however, despite DNA damage, the absence of RexAB did not sensitise *S.*
 291 *aureus rexB::Tn* mutants to linezolid or chloramphenicol but did increase susceptibility to

gentamicin. This may be explained by differences in the type of DNA damage caused by each of the antibiotics. Whilst several different types of DNA damage trigger SOS, only those leading to DSBs would be expected to promote susceptibility of the *rexBA* mutant [37,45,46,47]. As such, it is possible that bactericidal antibiotics trigger the potentially lethal DNA DSBs, whilst bacteriostatic antibiotics trigger non-lethal types of DNA damage. In keeping with this hypothesis, the absence of RexAB had only a small effect on SOS induction in *S. aureus* caused by linezolid or chloramphenicol. It is unclear why gentamicin did not trigger SOS during antibiotic exposure since it appeared to cause DNA DSBs in the antibiotic tolerance assays, but it may be the case that high concentrations of the antibiotic are needed for DNA damage. Combined, our data indicates differences between antibiotics in the degree of DNA damage caused, as well as the time required to cause damage and these differences may explain some of the debate around the contribution of ROS to antibiotic-mediated killing. However, the data clearly demonstrate that DNA DSBs are a common consequence of the exposure of *S. aureus* to several different classes of antibiotics and that an inability to repair those DSBs increase bacterial susceptibility to the antibacterial drugs. These findings are similar to those reported for *E. coli*, where mutants defective for DNA DSB repair (defective for *recB* or *recC*) were more susceptible than the wild type to at least 8 different antibiotics [48]. Crucially, we found that disruption of DNA DSB repair restored quinolone susceptibility in an otherwise resistant strain of *S. aureus*, which is also similar to what has been seen in *E. coli* and *Klebsiella pneumoniae* [49]. We also found that an inability to repair DSBs restored oxacillin susceptibility in the JE2 MRSA strain, although it remains to be seen if this finding is applicable to other MRSA strains.

The identification of RexAB as important for staphylococcal survival during exposure to several different antibiotics, including the re-sensitisation of resistant strains to some antibiotics, makes this complex a potential target for novel therapeutics, particularly as the lack of RexAB homologues in eukaryotes reduces the likelihood of host toxicity [37,43,50,51]. Inhibitors of RexAB would be expected to enhance the bactericidal activity of several different classes of antibiotic, as well as reduce the induction of the mutagenic SOS response, which is associated with the emergence of antibiotic resistance and mutants that can resist host immune defences [52,53]. We have also recently shown that DNA DSB repair is important for staphylococcal resistance to host immune defences, in keeping with similar findings with several other bacterial pathogens, providing an additional potential benefit of targeting this complex [34,54,55,56,57].

In summary, staphylococcal DNA is damaged by several classes of bactericidal antibiotics resulting in DSBs that are processed by RexAB and trigger the SOS response for repair. Therefore, RexAB is a potential target for novel therapeutics that sensitise *S. aureus* to antibiotics.

Materials and Methods

Bacterial strains and culture conditions

The bacterial strains used in this study are listed in

Table 1. *S. aureus* was cultured in Tryptic Soy Broth (TSB) or Muller Hinton Broth (MHB) to stationary phase (18 h) at 37 °C, with shaking (180 rpm). Media were supplemented with antibiotics as required.

Table 1. Bacterial strains used in this study.

Strain	Description	Source
<i>Staphylococcus aureus</i>		
SH1000	<i>rsbU</i> ⁺ derivative of the laboratory strain 8325-4	39
SH1000 <i>rexB</i> ::Tn	SH1000 with a <i>bursa aurealis</i> transposon insertion in <i>rexB</i> , Ery ^r	30
SH1000 <i>rexB</i> ::Tn <i>pitet</i> empty	SH1000 with a <i>bursa aurealis</i> transposon insertion in <i>rexB</i> with integrated <i>pitet</i> empty plasmid, Ery ^r	30
SH1000 <i>rexB</i> ::Tn <i>pitet rexAB</i>	SH1000 with a <i>bursa aurealis</i> transposon insertion in <i>rexB</i> with integrated <i>pitet</i> with AHT-inducible <i>rexB</i> , Ery ^r	30
JE2	A derivative of CA-MRSA USA300 LAC, cured of plasmids	38
JE2 <i>rexB</i> ::Tn	JE2 with a <i>bursa aurealis</i> transposon insertion in <i>rexB</i> , Ery ^r	38
JE2 <i>rexB</i> ::Tn <i>pitet</i> empty	JE2 with a <i>bursa aurealis</i> transposon insertion in <i>rexB</i> with integrated <i>pitet</i> empty plasmid, Ery ^r	30
JE2 <i>rexB</i> ::Tn <i>pitet rexAB</i>	JE2 with a <i>bursa aurealis</i> transposon insertion in <i>rexB</i> with integrated <i>pitet</i> with AHT-inducible <i>rexB</i> , Ery ^r	30
JE2 pCN34 <i>PrecA-gfp</i>	JE2 containing pCN34 with <i>gfp</i> under the control of the <i>recA</i> promoter, Kan ^r	30
JE2 <i>rexB</i> ::Tn pCN34 <i>PrecA-gfp</i>	JE2 <i>rexB</i> ::Tn containing pCN34 with <i>gfp</i> under the control of the <i>recA</i> promoter, Kan ^r	30

recA-gfp fluorescent reporter assay

As described previously [30,34], promoter-reporter gene constructs in JE2 and SH1000 backgrounds were used to quantify expression of *recA*. Antibiotic two-fold dilutions were made in flat-bottomed black-walled 96-well plates containing TSB and inoculated with 1/10 dilution of a stationary phase culture of the reporter strains. Plates were placed into an Infinite M200-PRO microplate reader (Tecan) where cultures were grown for 17 h at 37 °C (700 rpm), and both absorbance at 600 nm

(OD₆₀₀) and GFP relative fluorescence units (RFU) were measured every 30 min. To account for differences in cell-density, RFU values were normalised by OD₆₀₀ data at each time point.

Determination of minimum inhibitory concentration (MIC)

Minimum inhibitory concentrations (MICs) were determined using a serial broth dilution protocol as described previously [30, 58]. Bacteria were diluted to 1×10^5 CFU ml⁻¹ and incubated in flat-bottomed 96-well plates with a range of antibiotic concentrations for 17 h at 37 °C under static conditions (aerobic, anaerobic or 5% CO₂). Media containing daptomycin was supplemented with 1.25 mM CaCl₂. The MIC was defined as the lowest concentration at which no growth was observed.

Antibiotic survival assay

Bacteria were adjusted to 10^8 CFU ml⁻¹ in TSB (*S. aureus*) supplemented with antibiotics at 10X MIC. For aerobic incubation, 3 ml of media were inoculated in 30 ml universal tubes and incubated with shaking at 180 rpm. For anaerobic conditions 6 ml of pre-reduced media in 7 ml bijoux tubes was inoculated and incubated statically in an anaerobic cabinet. Cultures were incubated at 37 °C and bacterial viability determined by CFU counts. Culture media containing daptomycin was supplemented with 1.25 mM CaCl₂. Survival was calculated as a percentage of the number of bacteria in the starting inoculum.

Statistical analyses

Data are represented as the mean or median from three or more independent experiments and analysed by one-way ANOVA corrected for multiple comparison, as described in the figure legends. For each experiment, “n” refers to the number of independent biological replicates. P < 0.05 was considered significant between data points (GraphPad Prism 7 for Windows).

377

378

379 Acknowledgements

380 A.M.E. and R.S.C. acknowledge funding from Shionogi & Co., Ltd. A.M.E. also acknowledges support
381 from the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC).
382 Both authors acknowledge the provision of strains by the Network on Antimicrobial Resistance in
383 *Staphylococcus aureus* (NARSA) Program: under NIAID/ NIH Contract No. HHSN272200700055C. The
384 funders had no role in the study design, interpretation of the findings or the writing of the
385 manuscript.

386

387

388 References

- 389 1. Lowy FD. *Staphylococcus aureus* infections. 1998. *N Engl J Med* **339**: 520–532.
- 390 2. Fowler VG, Sakoulas G, McIntyre LM, Meka VG, Arbeit RD, Cabell CH, Stryjewski ME,
391 Eliopoulos GM, Reller LB, Corey GR, Jones T, Lucindo N, Yeaman MR, Bayer AS. 2004.
392 Persistent bacteremia due to methicillin-resistant *Staphylococcus aureus* infection is
393 associated with *agr* dysfunction and low-level *in vitro* resistance to thrombin-induced
394 platelet microbicidal protein. *J Infect Dis* **190**: 1140–1149.
- 395 3. Kreisel K, Boyd K, Langenberg P, Roghmann MC. 2006. Risk factors for recurrence in patients
396 with *Staphylococcus aureus* infections complicated by bacteremia. *Diagn Microbiol Infect*
397 *Dis*. **55**: 179–184.
- 398 4. Gordon RJ, Lowy FD. 2008. Pathogenesis of methicillin-resistant *Staphylococcus aureus*
399 infection. *Clin Infect Dis* **46**: S350–S359.
- 400 5. Chen C-J, Su L-H, Lin T-Y, Huang Y-C. 2010. Molecular analysis of repeated methicillin-
401 resistant *Staphylococcus aureus* infections in children. *PLoS One* **5**: e14431.
- 402 6. Peyrani P, Allen M, Seligson D, Roberts C, Chen A et al. 2012. Clinical outcomes of
403 osteomyelitis patients infected with methicillin-resistant *Staphylococcus aureus* USA-300
404 strains. *Am J Orthop* **41**: 117–122.
- 405 7. Tong SYC, Davis JS, Eichenberger E, Holland TL, Fowler VG. 2015. *Staphylococcus aureus*
406 infections: epidemiology, pathophysiology, clinical manifestations, and management. *Clin*
407 *Microbiol Rev*. **28**: 603–661.
- 408 8. Iung B, Duval X. 2019. Infective endocarditis: innovations in the management of an old
409 disease. *Nat Rev Cardiol* **16**: 623–635.
- 410 9. Kuehl R, Morata L, Meylan S, Mensa J, Soriano A. 2020. When antibiotics fail: a clinical and
411 microbiological perspective on antibiotic tolerance and persistence of *Staphylococcus*
412 *aureus*. *J Antimicrob Chemother* **75**: 1071–1086.
- 413 10. Urish KL, Cassat JE. 2020. *Staphylococcus aureus* Osteomyelitis: bone, bugs, and surgery.
414 *Infect Immun* **88**: e00932–19.
- 415 11. Greulich P, Scott M, Evans MR, Allen RJ. 2015. Growth-dependent bacterial susceptibility to
416 ribosome-targeting antibiotics. *Mol Syst Biol* **11**: 796.
- 417 12. Lee AJ, Wang S, Meredith HR, Zhuang B, Dai Z, You L. 2018. Robust, linear correlations
418 between growth rates and β -lactam-mediated lysis rates. *Proc Natl Acad Sci USA* **115**: 4069–
419 4074.
- 420 13. Haugan MS, Løbner-Olesen A, Frimodt-Møller N. 2019. Comparative activity of ceftriaxone,
421 ciprofloxacin, and gentamicin as a function of bacterial growth rate probed by *Escherichia*

- 422 *coli* chromosome replication in the mouse peritonitis model. *Antimicrob Agents Chemother*
423 **63**: e02133–18.
- 424 14. Lopatkin AJ, Stokes JM, Zheng EJ, Yang JH, Takahashi MK, You L, Collins JJ. 2019. Bacterial
425 metabolic state more accurately predicts antibiotic lethality than growth rate. *Nat Microbiol*
426 **4**: 2109-2117.
- 427 15. Kohanski MA, Dwyer DJ, Hayete B, Lawrence CA, Collins JJ. 2007. A common mechanism of
428 cellular death induced by bactericidal antibiotics *Cell* **130**: 797-810.
- 429 16. Wang X, Zhao X. 2009. Contribution of oxidative damage to antimicrobial lethality.
430 *Antimicrob Agents Chemother* **53**: 1395-1402.
- 431 17. Shatalin K, Shatalina E, Mironov A, Nudler E. 2011. H₂S: A universal defense against
432 antibiotics in bacteria. *Science* **334**: 986-990.
- 433 18. Calhoun LN, Kwon YM. 2011. The ferritin-like protein Dps protects *Salmonella enterica*
434 serotype Enteritidis from the Fenton-mediated killing mechanism of bactericidal antibiotics.
435 *Int J Antimicrob Agents* **37**: 261-265.
- 436 19. Foti JJ, Devadoss B, Winkler JA, Collins JJ, Walker GC. 2012. Oxidation of the guanine
437 nucleotide pool underlies cell death by bactericidal antibiotics. *Science* **336**: 315-319.
- 438 20. Liu Y, Liu X, Qu Y, Wang X, Li L, Zhao X. 2012. Inhibitors of reactive oxygen species
439 accumulation delay and/or reduce the lethality of several antistaphylococcal agents.
440 *Antimicrob Agents Chemother* **56**: 6048-6050.
- 441 21. Sampson TR, Liu X, Schroeder MR, Kraft CS, Burd EM, Weiss DS. 2012. Rapid killing of
442 *Acinetobacter baumannii* by polymyxins is mediated by a hydroxyl radical death pathway.
443 *Antimicrob Agents Chemother* **56**: 5642-5649.
- 444 22. Dwyer DJ, Belenky PA, Yang JH, MacDonald IC, Martell JD, Takahashi N, Chan CT, Lobritz MA,
445 Braff D, Schwarz EG, Ye JD, Pati M, Vercruysse M, Ralifo PS, Allison KR, Khalil AS, Ting AY,
446 Walker GC, Collins JJ. 2014. Antibiotics induce redox-related physiological alterations as part
447 of their lethality. *Proc Natl Acad Sci U S A* **111**(20) E2100-9.
- 448 23. Repine JE, Fox RB, Berger EM. 1981. Hydrogen peroxide kills *Staphylococcus aureus* by
449 reacting with staphylococcal iron to form hydroxyl radical. *J Biol Chem* **256**: 7094-7096.
- 450 24. Imlay JA, Chin SM, Linn S. 1988. Toxic DNA damage by hydrogen peroxide through the
451 Fenton reaction *in vivo* and *in vitro*. *Science* **240**: 640-642.
- 452 25. Imlay JA. 2003. Pathways of Oxidative Damage. *Annu Rev Microbiol* **57**: 395-418.
- 453 26. Fang FC. 2011. Antimicrobial actions of reactive oxygen species. *mBio* **2**: e00141-11.
- 454 27. Liu Y, Imlay JA. 2013. Cell death from antibiotics without the involvement of reactive oxygen
455 species. *Science*. **339**: 1210-3.
- 456 28. Keren I, Wu Y, Inocencio J, Mulcahy LR, Lewis K. 2013. Killing by bactericidal antibiotics does
457 not depend on reactive oxygen species. *Science*. **339**: 1213-6.
- 458 29. Imlay JA. 2015. Diagnosing oxidative stress in bacteria: not as easy as you might think. *Curr*
459 *Opin Microbiol* **24**: 124-31.
- 460 30. Clarke RS, Bruderer MS, Ha KP, Edwards AM. 2019. RexAB is essential for the mutagenic
461 repair of DNA damage caused by co-trimoxazole. *Antimicrob Agents Chemother* **63**: e00944.
- 462 31. Michel B. 2005. After 30 years of study, the bacterial SOS response still surprises us. *PLoS*
463 *Biol* **3**: e255.
- 464 32. Chang W, Small DA, Toghrol F, Bentley WE. 2006. Global transcriptome analysis of
465 *Staphylococcus aureus* response to hydrogen peroxide. *J Bacteriol* **188**: 1648-1659.
- 466 33. Cirz RT, Jones MB, Gingles NA, Minogue TD, Jarrahi B, Peterson SN, Romesberg FE. 2007.
467 Complete and SOS-mediated response of *Staphylococcus aureus* to the antibiotic
468 ciprofloxacin. *J Bacteriol* **189**: 531-539.
- 469 34. Ha KP, Clarke RS, Kim GL, Brittan JL, Rowley JE, Mavridou DA, Parker D, Clarke TB, Nobbs AH,
470 Edwards AM. 2020. Staphylococcal DNA Repair Is Required for Infection. *mBio* **11**: e02288-
471 20.
- 472 35. Maiques E, Ubeda C, Campoy S, Salvador N, Lasa I, Novick RP, Barbé J, Penades JR. 2006.

- 473 Beta-lactam antibiotics induce the SOS response and horizontal transfer of virulence factors
474 in *Staphylococcus aureus*. *J Bacteriol.* **188**: 2726-2729.
- 475 36. Cuirolo A, Plata K, Rosato AE. 2009. Development of homogeneous expression of resistance
476 in methicillin-resistant *Staphylococcus aureus* clinical strains is functionally associated with a
477 β -lactam-mediated SOS response. *J Antimicrob Chemother* **64**: 37-45.
- 478 37. Wigley DB. 2013. Bacterial DNA repair: recent insights into the mechanism of RecBCD,
479 AddAB and AdnAB. *Nat Rev Microbiol* **11**: 9-13.
- 480 38. Fey PD, Endres JL, Yajjala VK, Widhelm TJ, Boissy RJ, Bose JL, Bayles KW. 2013. A genetic
481 resource for rapid and comprehensive phenotype screening of nonessential *Staphylococcus*
482 *aureus* genes. *MBio* **4**: e00537-12.
- 483 39. Horsburgh MJ, Aish JL, White IJ, Shaw L, Lithgow JK, Foster SJ. 2002. sigmaB modulates
484 virulence determinant expression and stress resistance: characterization of a functional *rsbU*
485 strain derived from *Staphylococcus aureus* 8325-4. *J Bacteriol* **184**: 5457-67.
- 486 40. Drlica K. 1999. Mechanism of fluoroquinolone action. *Curr Opin Microbiol* **2**: 504-508.
- 487 41. Mates SM, Patel L, Kaback HR, Miller MH. 1983. Membrane potential in anaerobically
488 growing *Staphylococcus aureus* and its relationship to gentamicin uptake. *Antimicrob Agents*
489 *Chemother* **23**: 526-30.
- 490 42. Morrissey I, Smith JT. 1994. The importance of oxygen in the killing of bacteria by ofloxacin
491 and ciprofloxacin. *Microbios* **79**: 43-53
- 492 43. Lanyon-Hogg T. 2021. Targeting the bacterial SOS response for new antimicrobial agents:
493 drug targets, molecular mechanisms and inhibitors. *Future Med Chem* In Press
- 494 44. Miller C, Thomsen LE, Gaggero C, Mosseri R, Ingmer H, Cohen SN. 2004. SOS response
495 induction by beta-lactams and bacterial defense against antibiotic lethality. *Science*.
496 305(5690):1629-1631.
- 497 45. Rosato RR, Fernandez R, Paz LI, Singh CR, Rosato AE. 2014. TCA cycle-mediated generation of
498 ROS is a key mediator for HeR-MRSA survival under beta-lactam antibiotic exposure. *PLoS*
499 *One*. 9(6):e99605.
- 500 46. Chedin F, Kowalczykowski SC. 2002. A novel family of regulated helicases/nucleases from
501 Gram-positive bacteria: insights into the initiation of DNA recombination. *Mol Microbiol* **43**:
502 823-834.
- 503 47. Cromie GA. 2009. Phylogenetic ubiquity and shuffling of the bacterial RecBCD and AddAB
504 recombination complexes. *J Bacteriol* **191**: 5076-5084.
- 505 48. Liu A, Tran L, Becket E, Lee K, Chinn L, Park E, Tran K, Miller JH. 2010. Antibiotic sensitivity
506 profiles determined with an *Escherichia coli* gene knockout collection: generating an
507 antibiotic bar code. *Antimicrob Agents Chemother* **54**: 1393-403.
- 508 49. Wilkinson M, Troman L, Wan Nur Ismah WA, Chaban Y, Avison MB, Dillingham MS, Wigley
509 DB. 2016. Structural basis for the inhibition of RecBCD by Gam and its synergistic
510 antibacterial effect with quinolones. *Elife* **5**: e22963.
- 511 50. Amundsen SK, Spicer T, Karabulut AC, et al. Small-Molecule Inhibitors of Bacterial AddAB and
512 RecBCD Helicase-Nuclease DNA Repair Enzymes. *ACS Chem Biol.* 2012;7(5):879-891.
- 513 51. Lim CSQ, Ha KP, Clarke RS, et al. Identification of a potent small-molecule inhibitor of
514 bacterial DNA repair that potentiates quinolone antibiotic activity in methicillin-resistant
515 *Staphylococcus aureus*. *Bioorganic Med Chem.* 2019; 27(20):114962.
- 516 52. Painter KL, Strange E, Parkhill J, Bamford KB, Armstrong-James D, Edwards AM. 2015.

517 *Staphylococcus aureus* adapts to oxidative stress by producing H₂O₂-resistant small-colony
518 variants via the SOS response. *Infect Immun* **83**: 1830-44.

519 53. Painter KL, Hall A, Ha KP, Edwards AM. The electron transport chain sensitizes
520 *Staphylococcus aureus* and *Enterococcus faecalis* to the oxidative burst. *Infect Immun*.
521 2017;85(12):e00659-17.

522 54. Mertens K, Lantsheer L, Ennis DG, Samuel JE. Constitutive SOS expression and damage-
523 inducible AddAB-mediated recombinational repair systems for *Coxiella burnetii* as potential
524 adaptations for survival within macrophages. *Mol Microbiol*. 2008;69(6):1411-1426.

525 55. Gourley CR, Negretti NM, Konkel ME. The food-borne pathogen *Campylobacter jejuni*
526 depends on the AddAB DNA repair system to defend against bile in the intestinal
527 environment. *Sci Rep*. 2017;7(1).

528 56. Amundsen SK, Fero J, Hansen LM, et al. *Helicobacter pylori* AddAB helicase-nuclease and
529 RecA promote recombination-related DNA repair and survival during stomach colonization.
530 *Mol Microbiol*. 2008;69(4):994-1007.

531 57. Cano DA, Pucciarelli MG, García-Del Portillo F, Casadesús J. Role of the RecBCD
532 recombination pathway in *Salmonella* virulence. *J Bacteriol*. 2002;184(2):592-595.

533 58. Wiegand I, Hilpert K, Hancock REW. 2008. Agar and broth dilution methods to
534 determine the minimal inhibitory concentration (MIC) of antimicrobial substances.
535 *Nat Protoc* **3**: 163-175.

536